Impact Capital Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.67M Buy
2,228
+5
+0.2% +$5.11K 0.73% 30
2026
Q1
$2.04M Buy
2,223
+513
+30% +$520K 0.62% 40
2025
Q4
$1.84M Buy
1,710
+87
+5% +$83.2K 0.54% 43
2025
Q3
$1.24M Sell
1,623
-77
-5% -$57.3K 0.37% 57
2025
Q2
$1.33M Buy
1,700
+15
+0.9% +$11.7K 0.43% 58
2025
Q1
$1.39M Buy
1,685
+224
+15% +$186K 0.5% 48
2024
Q4
$1.13M Buy
+1,461
New +$1.21M 0.4% 61

Other funds holding LLY

Impact Capital Partners's LLY Position: Q2 2026 in Review

Impact Capital Partners increased its Eli Lilly (LLY) stake by 0.22% in Q2 2026, buying an estimated $5.11K and bringing the position to 2,228 shares worth $2.67M. The position accounts for 0.73% of the portfolio, ranked #30.

Impact Capital Partners first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. 1,364 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Impact Capital Partners held 2,228 shares of Eli Lilly worth $2.67M as of Q2 2026.
  • Impact Capital Partners bought 5 Eli Lilly shares in Q2 2026, an estimated $5.11K.
  • Eli Lilly made up 0.73% of Impact Capital Partners's portfolio in Q2 2026, its #30 holding.
  • Impact Capital Partners first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • 1,364 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Impact Capital Partners's 13F filing for Q2 2026, filed 14 Jul 2026.